Editas Medicine (EDIT) Stock Forecast & Price Target

$2.77 -0.19 (-6.42%)

(As of 11/14/2024 ET)

Editas Medicine - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
6

Buy
7

Based on 13 Wall Street analysts who have issued ratings for Editas Medicine in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 6 have given a hold rating, and 7 have given a buy rating for EDIT.

Consensus Price Target

$9.08
227.92% Upside

According to the 13 analysts' twelve-month price targets for Editas Medicine, the average price target is $9.08. The highest price target for EDIT is $15.00, while the lowest price target for EDIT is $3.00. The average price target represents a forecasted upside of 227.92% from the current price of $2.77.

Get the Latest News and Ratings for EDIT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Editas Medicine and its competitors.

EDIT Analyst Ratings Over Time

Type	Current Forecast 11/15/23 to 11/14/24	1 Month Ago 10/16/23 to 10/15/24	3 Months Ago 8/17/23 to 8/16/24	1 Year Ago 11/15/22 to 11/15/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	7 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$9.08	$10.22	$11.50	$15.19
Forecasted Upside	227.92% Upside	204.23% Upside	187.50% Upside	71.80% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Hold

Nvidia’s world of pain awaits (Ad)

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Click play to stream The Final Frontier at no cost

EDIT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EDIT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Editas Medicine Stock vs. The Competition

Type	Editas Medicine	Medical Companies	S&P 500
Consensus Rating Score	2.54	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	213.22% Upside	25,343.24% Upside	8.16% Upside
News Sentiment Rating	Neutral News See Recent EDIT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/6/2024	Evercore ISI 2 of 5 stars	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-line ➝ Outperform
11/5/2024	Chardan Capital 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00	+284.61%
11/5/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Sector Perform ➝ Sector Perform	$8.00 ➝ $5.00	+62.87%
11/5/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$17.00 ➝ $11.00	+264.24%
11/5/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$9.00 ➝ $7.00	+137.29%
11/5/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$12.00 ➝ $8.00	+171.19%
Get the Latest News and Ratings for EDIT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.
11/5/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $5.00	+77.30%
11/4/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Seedhouse Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/8/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$13.00 ➝ $15.00	+264.96%
6/18/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform	$12.00 ➝ $12.00	+138.57%
5/9/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$16.00 ➝ $15.00	+174.22%
5/9/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$7.00	+39.03%
2/27/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$8.00 ➝ $9.00	+3.09%
10/17/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
2/23/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$13.00 ➝ $15.00	+52.91%
1/23/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform	$6.00 ➝ $7.00	-14.43%
11/18/2022	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$25.00 ➝ $18.00	+63.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:38 PM ET.

EDIT Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Editas Medicine is $9.08, with a high forecast of $15.00 and a low forecast of $3.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EDIT shares.
: According to analysts, Editas Medicine's stock has a predicted upside of 227.92% based on their 12-month stock forecasts.
: Over the previous 90 days, Editas Medicine's stock had 1 upgrade and 1 downgrade by analysts.
: Editas Medicine has been rated by research analysts at Barclays, Chardan Capital, Evercore ISI, Raymond James, Royal Bank of Canada, Stifel Nicolaus, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Editas Medicine less than other "medical" companies. The consensus rating score for Editas Medicine is 2.54 while the average consensus rating score for "medical" companies is 2.80. Learn more on how EDIT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The next assassination attempt won’t be on Trump (Ad)

President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.

I share with you in this special investigative documentary.

This page (NASDAQ:EDIT) was last updated on 11/14/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Stock Forecast & Price Target